During the recent session, Allogene Therapeutics Inc (NASDAQ:ALLO)’s traded shares were 4.84 million, with the beta value of the company hitting 1.05. At the last check today, the stock’s price was $1.89, reflecting an intraday gain of 33.99% or $0.48. The 52-week high for the ALLO share is $5.78, that puts it down -205.82 from that peak though still a striking 30.16% gain since the share price plummeted to a 52-week low of $1.32. The company’s market capitalization is $396.14M, and the average intraday trading volume over the past 10 days was 2.73 million shares, and the average trade volume was 2.72 million shares over the past three months.
Allogene Therapeutics Inc (ALLO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.56. ALLO has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.33.
Allogene Therapeutics Inc (NASDAQ:ALLO) trade information
Allogene Therapeutics Inc (ALLO) registered a 33.99% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 33.99% in intraday trading to $1.89, hitting a weekly high. The stock’s 5-day price performance is 25.12%, and it has moved by 1.03% in 30 days. Based on these gigs, the overall price performance for the year is -59.02%. The short interest in Allogene Therapeutics Inc (NASDAQ:ALLO) is 32.05 million shares and it means that shorts have 11.7 day(s) to cover.
The consensus price target of analysts on Wall Street is $33.5, which implies an increase of 94.36% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $55 respectively. As a result, ALLO is trading at a discount of -2810.05% off the target high and -270.37% off the low.
Allogene Therapeutics Inc (ALLO) estimates and forecasts
In the rating firms’ projections, revenue will decrease -68.42% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 10.5k as predicted by 16 analyst(s). Meanwhile, a consensus of 12 analyst(s) estimates revenue growth to 4.17k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 21k and 22k respectively. In this case, analysts expect current quarter sales to shrink by -50.00% and then drop by -81.05% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 22.18%. While earnings are projected to return 36.25% in 2025, the next five years will return 11.41% per annum.
ALLO Dividends
Allogene Therapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Allogene Therapeutics Inc (NASDAQ:ALLO)’s Major holders
Allogene Therapeutics Inc insiders own 18.62% of total outstanding shares while institutional holders control 76.40%, with the float percentage being 93.89%. FMR LLC is the largest shareholder of the company, while 232.0 institutions own stock in it. As of 2024-06-30, the company held over 31.26 million shares (or 16.4491% of all shares), a total value of $72.83 million in shares.
The next largest institutional holding, with 18.72 million shares, is of TPG GP A, LLC’s that is approximately 11.0663% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $43.61 million.
Also, the Mutual Funds coming in first place with the largest holdings of Allogene Therapeutics Inc (ALLO) shares are Smallcap World Fund and Vanguard Total Stock Market Index Fund. Data provided on Sep 30, 2024 indicates that Smallcap World Fund owns about 6.9 shares. This amounts to just over 3.29 percent of the company’s overall shares, with a $12.7 million market value. The same data shows that the other fund manager holds slightly less at 4.34, or about 2.07% of the stock, which is worth about $7.99 million.
